Table 5.

ORs for risk of 28-day ACM for the final logistic regression model

Participant characteristic	OR for 28-day ACM (95% CI)
No vasopressor use versus concomitant vasopressor usea	0.12 (0.04 to 0.34)
Ceftolozane/tazobactam treatment versus meropenem treatmentb	0.23 (0.08 to 0.68)

OR estimates and CIs associated with the significant factors included into the final logistic regression model, each adjusted for the other factors

ACM All-cause mortality, OR Odds ratio

^aAdjusting for treatment

^bAdjusting for vasopressor use